Table 48 (abstract P173). Clinical and disease characteristics of the two patients at tocilizumab initiation
From: Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part one
Patient characteristics | Patient I | Patient II |
|---|---|---|
Age | 11 months | 18 months |
Ethnicity | Caucasian | Caucasian |
Gender | male | female |
Disease duration | 3 months | 7 months |
Steroid dose | 2 mg/kg/day | 1 mg/kg/day |
Methotrexate dose (SC) | 15 mg/m2 | 15 mg/m2 |
Tocilizumab dose (IV) | 12 mg/kg every two weeks | 12 mg/kg every two weeks |
ACR Pedi 30 (+ no fever) | By week 12 | By week 8 |
ACR Pedi 90 (+no fever) | By week 36 | By week 24 |
Adverse events | Varicella | Recurrent upper respiratory tract infections |